Amplia's Lilly Deal Gives ATX a Near-Term Runway-But Lung Cancer Validation Is the Only Thing That Matters

Lilly expands Amplia's access to NSCLC, not its proof set

What changed

Amplia's new clinical trial collaboration and supply agreement with Eli Lilly creates a path to test narmafotinib with Lilly's KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer (NSCLC). The Phase 1b/2b study is expected to begin in late 2026.

For now, the significance is strategic rather than fundamental. Amplia is extending narmafotinib beyond its established pancreatic and ovarian cancer programs into a larger oncology indication, and the partnership gives the company exposure to a broader development pathway than it had before.

Why NSCLC matters

The NSCLC market is already worth about US$31 billion. Lilly also has two separate, global Phase 3 registrational trials underway with olomorasib in NSCLC, which gives the partnership more weight than a routine research announcement. Even so, that late-stage momentum belongs to Lilly's program; it does not yet transfer to Amplia.

Why the deal has more weight than a typical biotech headline

Protocol work was already well advanced

Amplia and Lilly had already developed an advanced draft of the clinical study protocol before signing. That suggests the teams were close to aligning on key design elements before the agreement was finalized, which makes the deal look more like a practical trial setup than a publicity-led partnership.

Lilly is contributing drug supply

Lilly will provide olomorasib for the trial at no cost. The agreement is also described as an in-kind supply arrangement. That does not guarantee success, but it does reduce Amplia's burden and supports the view that the trial has a realistic path to starting.

The expansion broadens narmafotinib's potential platform

The collaboration moves narmafotinib into NSCLC, a much larger market than some of Amplia's earlier programs. If the combination eventually shows biological activity, that would broaden the commercial case beyond Amplia's current indication base.

The bear case: partnership access is not validation

This is still a Phase 1b/2b study that needs to show signal in lung cancer. Investors should keep two points separate:

• Lilly's involvement improves trial plausibility and execution setup.
• It does not prove narmafotinib will work in this indication.

That caution matters because Amplia's trading profile remains milestone-driven. The company has said its share performance is likely to remain closely linked to clinical milestones, so a prestigious partnership is not the same as clinical proof.

What would actually reprice ATX

The study is expected to begin in late 2026, and the immediate next steps are finalizing the protocol and related documents. For investors, that creates a short list of practical checkpoints:

• protocol finalization and trial startup progress
• whether the study starts on schedule
• early safety and efficacy readouts from the combination

Lilly's broader Phase 3 registrational trials add credibility to the partnership, but they do not replace Amplia's own data.

The clean bull case

A meaningful rerating would come from the Phase 1b/2b study showing manageable safety and efficacy for narmafotinib plus olomorasib, with signs that FAK inhibition is adding clinical value on top of KRAS G12C blockade.

What would weaken the thesis

The setup weakens if the trial is delayed, if the combination shows tolerability problems, or if early readouts fail to suggest biological activity. In that sense, the Lilly deal gave ATX a more credible runway, but only lung cancer data can turn that opportunity into validation.